Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

736.86 +21.30 (+2.98%)
Streaming Delayed Price Updated: 3:32 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Why Viking Therapeutics Stock Was Victorious This Week
Via The Motley Fool
Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential. 
Via Benzinga
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors. 
Via The Motley Fool
Topics World Trade
Exposures Tariff
Eli Lilly's Options Frenzy: What You Need to Know
Via Benzinga
US Futures Rise As Apple, Amazon, Airbnb Earnings Boost Market Sentiment: S&P 500 Hits Milestone That's Preceded A 100% Win Rate Since 1956, Says Expert
U.S. stock futures are in the green early Friday, after another winning day for the markets in the regular session on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For May 1, 2025
Via Benzinga
Is Novo Nordisk Stock a Buy?
Via The Motley Fool
Exposures Product Safety
Where Will Viking Therapeutics Be in 3 Years?
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years. 
Via The Motley Fool
Topics Bankruptcy
Exposures Financial Legal
Market Monitor May 2 ( Microsoft, Meta UP - Eli Lilly DOWN)
Wall Street Rebounds as Microsoft and Meta Impress, Eyes Turn to Jobs Report and Tariff Tensions 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
Which S&P500 stocks have an unusual volume on Thursday?
Let's have a look at what is happening on the US markets on Thursday. Below you can find the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
Why Eli Lilly (LLY) Stock Is Nosediving
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported weak first quarter 2025 results which included an EPS miss due to... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Wall Street Eyes 8th Positive Day As S&P 500 Recoups Tariff-Led Losses, Bitcoin Rallies To $97,000: What's Driving Markets Thursday?
Wall Street pushed higher in midday trading, with the S&P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully... 
Via Benzinga
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Eli Lilly Stock Is Sinking Today
Via The Motley Fool
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Thursday's session: gap up and gap down stock in the S&P500 index
Curious about the S&P500 stocks that are gapping on Thursday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
These S&P500 stocks are moving in today's pre-market session
Get insights into the top gainers and losers in the S&P500 index of Thursday's pre-market session. 
Via Chartmill
Mounjaro Maker Eli Lilly Clocks 45% Jump In Q1 Revenue, Cuts 2025 Profit Outlook But Not Due To Tariffs
Eli Lilly cut its 2025 profit outlook after strong Q1 sales from Mounjaro and Zepbound and a $1.57 billion charge tied to a cancer drug acquisition. 
Via Benzinga
Eli Lilly Stock Falls After Zepbound Sales Miss, Full-Year Profit Outlook Cut
The company cut its adjusted earnings per share guidance for the full year to $22.50 to $24.00, down from its previous forecast of $20.78 to $22.28. 
Via Stocktwits
Topics Earnings Government
Exposures Financial Political
Eli Lilly Slumps 5% On Profit Guidance Cut Despite Mounjaro, Zepbound Beats
The drugmaker cut its profit guidance for the year, but kept its sales outlook. 
Via Investor's Business Daily
Beat the Nasdaq With This Cash-Gushing Dividend Stock
Via The Motley Fool
Topics Economy Stocks
Exposures Economy US Equities
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year? 
Via Investor's Business Daily
Topics Animal Testing Economy Government
Exposures Animal Testing Economy Political
Eli Lilly (NYSE:LLY) Beats Q1 Sales Targets
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 45.2% year on year to $12.73 billion. The company expects the... 
Via StockStory
US Stock Futures Rise As Meta, Microsoft Earnings Fuel Optimism: GDP Slump Linked To Tariff Anticipation, Not Recession, Says Analyst
U.S. stock futures rose early Thursday morning, following the robust earnings of two "Mag 7" companies after markets closed on Wednesday. 
Via Benzinga
Topics Economy
Exposures Economy
1 Beaten-Down Stock to Buy and Hold for 10 Years
Via The Motley Fool
Topics Economy
Exposures Economy
Where Is Hims & Hers Stock Headed After Wegovy Tie-Up? Retail Traders Bet On Rebound To Over 2-Month High
Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit its 2025 weight loss revenue guidance. 
Via Stocktwits
Exposures Product Safety
Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Nasdaq, Dow Jones Futures Rise On Meta, Microsoft Results: Apple Earnings Loom, Analyst Doubts New Bull Run For Stock Markets
Notwithstanding the recent seven-session run, the S&P 500 Index ended April — a historically strong month — with a loss of 0.8%. 
Via Stocktwits
Topics Economy Stocks World Trade
Exposures Fossil Fuels Interest Rates Tariff
New Weight Loss Pill & Massive U.S. Investment Sends Eli Lilly Stock Soaring – Is It Too Late To Buy?
Eli Lilly, a pharmaceutical leader in obesity and diabetes treatment, is back in the spotlight, and for good reason. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.